In a groundbreaking advance that may redefine the future of pandemic preparedness, scientists at the La Jolla Institute for Immunology (LJI) have unveiled a novel vaccine strategy aimed at combating the entire arenavirus family with a single, unified immunization. This “pan-arenavirus” vaccine approach leverages the intrinsic ability of human T cells to cross-recognize conserved viral epitopes, providing hope for broad protection against multiple arenaviruses, including lethal pathogens such as Lassa and Junin viruses, both notorious for their potential to cause deadly outbreaks.
The research team, led by Professor Alessandro Sette and co-led by Research Assistant Professor Alba Grifoni, has meticulously decoded the CD4+ T cell epitope repertoire specific to the Lassa fever virus, an Old World arenavirus responsible for tens of thousands of deaths annually, primarily in West Africa. Their pivotal findings, recently published in the journal Cell Reports Medicine, demonstrate that T cells are capable of recognizing shared epitopes conserved across all Old World arenavirus species. This discovery underscores the feasibility of designing a vaccine that could confer immunity beyond a single species, targeting a broader spectrum within this viral family.
Arenaviruses represent a complex and diverse group of segmented, single-stranded RNA viruses that have evolved over millennia into two distinct clades: Old World arenaviruses predominantly found in Africa, Europe, and Asia, and New World arenaviruses endemic to the Americas. The evolutionary divergence—estimated to have occurred roughly 45,000 years ago—has resulted in distinct viral epitopes between the two groups, posing challenges for cross-protective vaccine development. Intriguingly, LJI researchers found that while T cells could cross-react broadly within Old World species, they did not exhibit similar cross-reactivity toward New World arenaviruses.
To address this gap, the team expanded their scope by investigating the epitope landscape and T cell responses against the Junin virus, a New World arenavirus responsible for Argentine hemorrhagic fever. Utilizing samples from vaccinated individuals in Argentina who had prior exposure to Junin viral antigens, the scientists identified T cell subsets capable of recognizing conserved epitopes shared among several New World arenavirus species. This critical insight led to the proposal that a dual-immunogen vaccine, incorporating epitopes from both Old World and New World arenaviruses, could evoke cross-protective T cell responses, delivering comprehensive immunity across the arenavirus family.
The mechanistic underpinnings of this innovative strategy hinge on the adaptive immune system’s remarkable capacity to mount and maintain memory T cell responses against viral epitopes—specific protein fragments presented by infected cells that act as molecular beacons for immune recognition. By targeting highly conserved epitopes, which are less susceptible to genetic drift and mutation, such vaccines can maintain efficacy even as viral populations evolve. This contrasts with traditional vaccine approaches that often focus on neutralizing antibodies targeting mutable viral surface proteins, which may rapidly change and lead to immune escape.
Moreover, the research holds implications beyond arenaviruses alone. The study illuminates the broader paradigm of harnessing cross-reactive T cell responses for pan-viral vaccine design, a concept particularly pressing in the context of other segmented RNA viruses such as hantaviruses. Recent outbreaks of Andes hantavirus—another rodent-borne segmented RNA virus that has demonstrated unusual human-to-human transmissibility—have galvanized interest in broadly protective vaccines. The parallels in viral structure and transmission dynamics between arenaviruses and hantaviruses suggest that leveraging conserved T cell epitopes may also inform strategies against emerging hantavirus threats.
The urgency of this research is heightened by the persistent global health threat posed by arenaviruses, many of which are zoonotic pathogens with established reservoirs in rodent populations. Spillover events can precipitate localized epidemics or even pandemics, particularly in regions with dense human-rodent interactions. Lassa virus alone is estimated to infect hundreds of thousands yearly, causing hemorrhagic fever with case fatality rates up to 30% in hospitalized patients. Notably, existing vaccine efforts focus largely on individual arenavirus species, with experimental vaccines for Lassa virus already progressing but with limited cross-protection.
LJI’s study also underscores the importance of employing advanced immunological tools to dissect the human T cell repertoire against viral epitopes, highlighting the sophistication and sensitivity required to pinpoint cross-reactive epitopes suitable for vaccine development. The interdisciplinary team integrated experimental immunology with computational epitope prediction and validation, supported by funding from prominent agencies such as the National Institutes of Health’s National Institute of Allergy and Infectious Diseases and the Coalition for Epidemic Preparedness Innovations (CEPI).
The promise of a pan-arenavirus vaccine extends beyond immediate public health needs, offering a strategic blueprint for preparing against future viral emergences. Given the ability of certain arenaviruses to cause severe hemorrhagic diseases and their potential for pandemic spread, the scientific community stands at the threshold of a new era where vaccines could preemptively guard against multiple viruses, even those yet to cross into human populations.
Professor Sette emphasizes that this research forms a critical foundation for rapid vaccine design when outbreaks arise. “By chipping away at the molecular commonalities within viral families, we equip ourselves with the data necessary to expedite vaccine creation during emergencies,” he states. The work by Sette, Grifoni, and colleagues exemplifies the frontier of immunogen design, moving beyond species-specific vaccines and toward universal approaches driven by detailed T cell memory insights.
In tandem with arenavirus research, the LJI team is also applying these methodologies to other viral families with significant epidemic potential, encompassing paramyxoviruses like measles and togaviruses such as Chikungunya. The overarching strategy focuses on decoding the adaptive immune response at a granular epitope level, revealing vulnerabilities common to viral relatives and harnessing the versatility of T cells to provide a robust defense.
As the global scientific community intensifies efforts to anticipate and neutralize viral threats, these innovative vaccine concepts hold exceptional promise. Leveraging the cross-reactivity of T cell responses may ultimately transform vaccine technology, enabling multivalent or universal vaccines that tackle not only current viral scourges but also those yet to emerge from nature’s vast reservoir of pathogens.
Subject of Research: Cells
Article Title: Decoding the human CD4+ T cell epitope repertoire for Lassa fever virus reveals T-cell based pan-mammarenavirus vaccine candidates
News Publication Date: 19-May-2026
Web References:
Cell Reports Medicine Article
DOI Link
References:
Siddiqui L, Tarke A, Kim M, Michaelis T, Macias M, Phillips E, Mallal S, Trevizani R, Frazier A, Scheuermann RH, Zuniga A, Zmasek C, Spurgers K, Akintunde G, Stonier SW, Gagliardi TB, Warfield K, Li H, Hastie KM, Ollmann Saphire E, Tan GS, Grifoni A, Sette A. Decoding the Human CD4+ T cell Epitope Repertoire for Lassa Fever Virus Reveals Novel Pan-mammarenavirus Vaccine Candidates. Cell Reports Medicine. 2026 May 19; doi:10.1016/j.xcrm.2026.102824.
Keywords: Vaccine research, Arenaviruses, T cells, Cross-reactive T cell epitopes, Pan-arenavirus vaccine, Lassa virus, Junin virus, Old World arenaviruses, New World arenaviruses, Adaptive immune response, Pandemic preparedness, Hantaviruses.
Tags: arenavirus family viral outbreaksbroad-spectrum arenavirus vaccineCD4+ T cell epitope mappingconserved viral epitopes in arenavirusescross-protective T cell responsesimmune response to Old World arenavirusesLassa fever virus immunologynovel vaccine approaches for viral familiespan-arenavirus vaccine developmentpandemic preparedness through universal vaccinesT cell cross-recognition in viral immunityvaccine strategies against RNA viruses
